Targeting human medulloblastoma

oncolytic virotherapy with myxoma virus is enhanced by rapamycin

Qing Lun Xue, Hongyuan Zhou, Tommy Alain, Beichen Sun, Limei Wang, John W. Barrett, Marianne M. Stanford, Douglas McFadden, John Bell, Donna L. Senger, Peter A. Forsyth

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

We have shown previously the oncolytic potential of myxoma virus in a murine xenograft model of human glioma. Here, we show that myxoma virus used alone or in combination with rapamycin is effective and safe when used in experimental models of medulloblastoma in vitro and in vivo. Nine of 10 medulloblastoma cell lines tested were susceptible to lethal myxoma virus infection, and pretreatment of cells with rapamycin increased the extent of in vitro oncolysis. Intratumoral injection of live myxoma virus when compared with control inactivated virus prolonged survival in D341 and Daoy orthotopic human medulloblastoma xenograft mouse models [D341 median survival: 21 versus 12.5 days; P = 0.0008; Daoy median survival: not reached (three of five mice apparently "cured" after 223 days) versus 75 days; P = 0.0021]. Rapamycin increased the extent of viral oncolysis, "curing" most Daoy tumor-bearing mice and reducing or eliminating spinal cord and ventricle metastases. Rapamycin enhanced tumor-specific myxoma virus replication in vivo and prolonged survival of D341 tumor-bearing mice (median survival of mice treated with live virus (LV) and rapamycin, versus LV alone, versus rapamycin alone, versus inactivated virus: 25 days versus 19, 13, and 11 days, respectively; P < 0.0001). Rapamycin increased the levels of constitutively activated Akt in Daoy and D341 cells, which may explain its ability to enhance myxoma virus oncolysis. These observations suggest that myxoma virus may be an effective oncolytic agent against medulloblastoma and that combination therapy with signaling inhibitors that modulate activity of the phosphatidylinositol 3-kinase/Akt pathway will further enhance the oncolytic potential of myxoma virus.

Original languageEnglish (US)
Pages (from-to)8818-8827
Number of pages10
JournalCancer Research
Volume67
Issue number18
DOIs
StatePublished - Sep 15 2007
Externally publishedYes

Fingerprint

Myxoma virus
Oncolytic Virotherapy
Medulloblastoma
Sirolimus
Viruses
Survival
Heterografts
Phosphatidylinositol 3-Kinase
Neoplasms
Virus Diseases
Virus Replication
Glioma
Spinal Cord
Theoretical Models
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Xue, Q. L., Zhou, H., Alain, T., Sun, B., Wang, L., Barrett, J. W., ... Forsyth, P. A. (2007). Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Research, 67(18), 8818-8827. https://doi.org/10.1158/0008-5472.CAN-07-1214

Targeting human medulloblastoma : oncolytic virotherapy with myxoma virus is enhanced by rapamycin. / Xue, Qing Lun; Zhou, Hongyuan; Alain, Tommy; Sun, Beichen; Wang, Limei; Barrett, John W.; Stanford, Marianne M.; McFadden, Douglas; Bell, John; Senger, Donna L.; Forsyth, Peter A.

In: Cancer Research, Vol. 67, No. 18, 15.09.2007, p. 8818-8827.

Research output: Contribution to journalArticle

Xue, QL, Zhou, H, Alain, T, Sun, B, Wang, L, Barrett, JW, Stanford, MM, McFadden, D, Bell, J, Senger, DL & Forsyth, PA 2007, 'Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin', Cancer Research, vol. 67, no. 18, pp. 8818-8827. https://doi.org/10.1158/0008-5472.CAN-07-1214
Xue, Qing Lun ; Zhou, Hongyuan ; Alain, Tommy ; Sun, Beichen ; Wang, Limei ; Barrett, John W. ; Stanford, Marianne M. ; McFadden, Douglas ; Bell, John ; Senger, Donna L. ; Forsyth, Peter A. / Targeting human medulloblastoma : oncolytic virotherapy with myxoma virus is enhanced by rapamycin. In: Cancer Research. 2007 ; Vol. 67, No. 18. pp. 8818-8827.
@article{39bc9b92edef4f509584c51b967018b1,
title = "Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin",
abstract = "We have shown previously the oncolytic potential of myxoma virus in a murine xenograft model of human glioma. Here, we show that myxoma virus used alone or in combination with rapamycin is effective and safe when used in experimental models of medulloblastoma in vitro and in vivo. Nine of 10 medulloblastoma cell lines tested were susceptible to lethal myxoma virus infection, and pretreatment of cells with rapamycin increased the extent of in vitro oncolysis. Intratumoral injection of live myxoma virus when compared with control inactivated virus prolonged survival in D341 and Daoy orthotopic human medulloblastoma xenograft mouse models [D341 median survival: 21 versus 12.5 days; P = 0.0008; Daoy median survival: not reached (three of five mice apparently {"}cured{"} after 223 days) versus 75 days; P = 0.0021]. Rapamycin increased the extent of viral oncolysis, {"}curing{"} most Daoy tumor-bearing mice and reducing or eliminating spinal cord and ventricle metastases. Rapamycin enhanced tumor-specific myxoma virus replication in vivo and prolonged survival of D341 tumor-bearing mice (median survival of mice treated with live virus (LV) and rapamycin, versus LV alone, versus rapamycin alone, versus inactivated virus: 25 days versus 19, 13, and 11 days, respectively; P < 0.0001). Rapamycin increased the levels of constitutively activated Akt in Daoy and D341 cells, which may explain its ability to enhance myxoma virus oncolysis. These observations suggest that myxoma virus may be an effective oncolytic agent against medulloblastoma and that combination therapy with signaling inhibitors that modulate activity of the phosphatidylinositol 3-kinase/Akt pathway will further enhance the oncolytic potential of myxoma virus.",
author = "Xue, {Qing Lun} and Hongyuan Zhou and Tommy Alain and Beichen Sun and Limei Wang and Barrett, {John W.} and Stanford, {Marianne M.} and Douglas McFadden and John Bell and Senger, {Donna L.} and Forsyth, {Peter A.}",
year = "2007",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-07-1214",
language = "English (US)",
volume = "67",
pages = "8818--8827",
journal = "Cancer Research",
issn = "0008-5472",
number = "18",

}

TY - JOUR

T1 - Targeting human medulloblastoma

T2 - oncolytic virotherapy with myxoma virus is enhanced by rapamycin

AU - Xue, Qing Lun

AU - Zhou, Hongyuan

AU - Alain, Tommy

AU - Sun, Beichen

AU - Wang, Limei

AU - Barrett, John W.

AU - Stanford, Marianne M.

AU - McFadden, Douglas

AU - Bell, John

AU - Senger, Donna L.

AU - Forsyth, Peter A.

PY - 2007/9/15

Y1 - 2007/9/15

N2 - We have shown previously the oncolytic potential of myxoma virus in a murine xenograft model of human glioma. Here, we show that myxoma virus used alone or in combination with rapamycin is effective and safe when used in experimental models of medulloblastoma in vitro and in vivo. Nine of 10 medulloblastoma cell lines tested were susceptible to lethal myxoma virus infection, and pretreatment of cells with rapamycin increased the extent of in vitro oncolysis. Intratumoral injection of live myxoma virus when compared with control inactivated virus prolonged survival in D341 and Daoy orthotopic human medulloblastoma xenograft mouse models [D341 median survival: 21 versus 12.5 days; P = 0.0008; Daoy median survival: not reached (three of five mice apparently "cured" after 223 days) versus 75 days; P = 0.0021]. Rapamycin increased the extent of viral oncolysis, "curing" most Daoy tumor-bearing mice and reducing or eliminating spinal cord and ventricle metastases. Rapamycin enhanced tumor-specific myxoma virus replication in vivo and prolonged survival of D341 tumor-bearing mice (median survival of mice treated with live virus (LV) and rapamycin, versus LV alone, versus rapamycin alone, versus inactivated virus: 25 days versus 19, 13, and 11 days, respectively; P < 0.0001). Rapamycin increased the levels of constitutively activated Akt in Daoy and D341 cells, which may explain its ability to enhance myxoma virus oncolysis. These observations suggest that myxoma virus may be an effective oncolytic agent against medulloblastoma and that combination therapy with signaling inhibitors that modulate activity of the phosphatidylinositol 3-kinase/Akt pathway will further enhance the oncolytic potential of myxoma virus.

AB - We have shown previously the oncolytic potential of myxoma virus in a murine xenograft model of human glioma. Here, we show that myxoma virus used alone or in combination with rapamycin is effective and safe when used in experimental models of medulloblastoma in vitro and in vivo. Nine of 10 medulloblastoma cell lines tested were susceptible to lethal myxoma virus infection, and pretreatment of cells with rapamycin increased the extent of in vitro oncolysis. Intratumoral injection of live myxoma virus when compared with control inactivated virus prolonged survival in D341 and Daoy orthotopic human medulloblastoma xenograft mouse models [D341 median survival: 21 versus 12.5 days; P = 0.0008; Daoy median survival: not reached (three of five mice apparently "cured" after 223 days) versus 75 days; P = 0.0021]. Rapamycin increased the extent of viral oncolysis, "curing" most Daoy tumor-bearing mice and reducing or eliminating spinal cord and ventricle metastases. Rapamycin enhanced tumor-specific myxoma virus replication in vivo and prolonged survival of D341 tumor-bearing mice (median survival of mice treated with live virus (LV) and rapamycin, versus LV alone, versus rapamycin alone, versus inactivated virus: 25 days versus 19, 13, and 11 days, respectively; P < 0.0001). Rapamycin increased the levels of constitutively activated Akt in Daoy and D341 cells, which may explain its ability to enhance myxoma virus oncolysis. These observations suggest that myxoma virus may be an effective oncolytic agent against medulloblastoma and that combination therapy with signaling inhibitors that modulate activity of the phosphatidylinositol 3-kinase/Akt pathway will further enhance the oncolytic potential of myxoma virus.

UR - http://www.scopus.com/inward/record.url?scp=34548714237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548714237&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-1214

DO - 10.1158/0008-5472.CAN-07-1214

M3 - Article

VL - 67

SP - 8818

EP - 8827

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -